摘要
目的通过观察瑞舒伐他汀治疗原发性高血压(EH)患者颈动脉内膜中层厚度(CAIMT)、血脂及血压水平变化,探讨瑞舒伐他汀对EH患者颈动脉粥样硬化(CAS)的影响,以及临床疗效观察。方法以128例EH患者为研究对象,治疗前后监测CAIMT值、血压及血脂,CAIMT值的测量采用彩色多普勒超声仪,据CAIMT值分组后采用常规及瑞舒伐他汀治疗,治疗6个月后观察其临床疗效。结果 (1)128例EH患者中79例CAIMT值>1.0mm(61.72%)为内膜增厚。(2)两组患者治疗前血脂水平差异无统计学意义(P>0.05)。治疗(6个月)后,CAIMT增厚组(瑞舒伐他汀治疗)的血脂水平变化有统计学意义(P<0.01),CAIMT值显著降低(t=7.902,P<0.01);常规治疗的CAIMT非增厚组血脂水平无显著性变化(P>0.05),但CAIMT值显著升高(t=3.017,P<0.01)。(3)瑞舒伐他汀治疗的CAIMT增厚组的显效率和总有效率(73.4%、93.7%)均显著高于CAIMT非增厚组(47.0%、65.4%),x2=16.228、19.530,P<0.01。结论瑞舒伐他汀可通过改善EH患者血脂水平及血管内皮细胞功能来改善或控制动脉粥样硬化的发生发展,提高临床疗效。
Objective To explore the effects and clinical curative effects of rosuvastatin on carotid atherosclerosis（CAS） in patients with essential hypertension（EH） through the observation of changes of carotid artery intima-media thickness（CAIMT）, blood lipid and blood pressure by rosuvastatin in the treatment of EH. Methods 128 patients with EH were selected as research subjects and CAIMT values, blood pressure and blood lipid were monitored before and after the treatment. Color Doppler ultrasound was used to measure the CAIMT values. The patients were assigned to two groups based on CAIMT values and received regular treatment and rosuvastatin respectively. Clinical effects were observed six months after treatment. Results （1）79 in 128 patients with EH had CAIMT value 〉 1.0mm（61.72%）, indicating the thickening of intima-media. （2）The differences of blood lipid levels between the two groups before treatment were not statistically significant（P 〉 0.05）. Six months after treatment, the difference of blood lipid change in the group with CAIMT thickening （with the treatment of rosuvastatin） was statistically significant（P 〈 0.01）, and CAIMT value significantly decreased（t=7.902, P 〈 0.01）; the difference of blood lipid change in the group with no CAIMT thickening （with regular treatment） was not statistically significant （P 〉 0.05）, but CAIMT value significantly increased（t=3.017,P 〈 0.01）. （3）The significant efficiency and total effective rate in the group with CAIMT thickening received the treatment of rosuvastatin （73.4%, 93.7%） were significantly higher than those in the group with no CAIMT thickening （47.0%, 65.4 %）,χ^2=16.228,19.530,P 〈 0.01. Conclusion Rosuvastatin helps improve the blood lipid level and vascular endothelial cells function of the patients with EH so as to control or alleviate the development of atherosclerosis, and thus improve clinical effects.
出处
《中国医药科学》
2014年第4期93-96,共4页
China Medicine And Pharmacy
关键词
原发性高血压
瑞舒伐他汀
颈动脉粥样硬化
临床疗效
Essential hypertension（EH）
Rosuvastatin
Carotid atherosclerosis（CAS）
Clinical effects
